Get the Stockscreener App
3.70
0.94%
0.00
Evaxion A S Adr stock is traded at $3.70, with a volume of 1,026.
It is up +0.94% in the last 24 hours and up +14.92% over the past month.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
See More
Previous Close:
$3.70
Open:
$3.76
24h Volume:
1,026
Relative Volume:
0.02
Market Cap:
$30.86M
Revenue:
$7.50M
Net Income/Loss:
$-7.79M
P/E Ratio:
-3.003
EPS:
-1.2321
Net Cash Flow:
$-24.56M
1W Performance:
-6.63%
1M Performance:
+14.92%
6M Performance:
-7.55%
1Y Performance:
+111.01%
1-Day Range:
$3.70
$3.76
1-Week Range:
$3.58
$4.0909
52-Week Range:
$1.20
$12.15
Evaxion A S Adr Stock (EVAX) Company Profile
Compare EVAX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
3.70 | 30.86M | 7.50M | -7.79M | -24.56M | -1.2321 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Maxim Group | Buy |
| Apr-02-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Feb-12-24 | Initiated | H.C. Wainwright | Buy |
Evaxion A S Adr Stock (EVAX) Latest News
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
Notice to convene Evaxion’s Annual General Meeting - GlobeNewswire Inc.
Europe’s US-Listed ADRs Rose, Led By Solar And Biotech - Finimize
Evaxion Biotech Earnings Call Highlights AI and Runway - TipRanks
European ADRs Rose, While Biotech Names Did The Heavy Lifting - Finimize
Evaxion A/S (NASDAQ:EVAX) Receives Buy Rating from HC Wainwright - Defense World
Evaxion A/S (NASDAQ:EVAX) Price Target Cut to $9.00 by Analysts at Lake Street Capital - Defense World
Evaxion Earnings Report: Q4 Overview - Sahm
Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Up 20.9% in February - Defense World
Evaxion Biotech's Earnings: A Preview - Sahm
European ADRs Slip Slightly As Winners And Losers Split - Finimize
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN
European ADRs Edge Higher Despite Mixed Stock Moves - Finimize
Brokerages Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Target Price at $12.33 - Defense World
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Sahm
European Firms Make Gains On US Markets As ADR Index Rises - Finimize
Evaxion Biotech Reports Strong Q3 2025 Results - MSN
Brokerages Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Price Target at $12.33 - Defense World
European ADRs Edge Up With Gains Led By Evaxion - Finimize
Evaxion Biotech’s Earnings Call Highlights Strategic Growth - TipRanks
Analysts Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) PT at $12.33 - Defense World
European Biotech Stocks Outperformed As Broader Market Dipped - Finimize
European ADRs Barely Budge While Gainers And Losers Trade Places - Finimize
Evaxion A/S (NASDAQ:EVAX) Given Buy Rating at HC Wainwright - Defense World
European ADRs Edge Higher As Healthcare Leads Gains - Finimize
Evaxion A S Adr Stock (EVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):